As of 2026-09-21, the Intrinsic Value of ALX Oncology Holdings Inc (ALXO) is -3.01 USD. This ALXO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.70 USD, the upside of ALX Oncology Holdings Inc is -276.81%.
Based on its market price of 1.70 USD and our intrinsic valuation, ALX Oncology Holdings Inc (ALXO) is overvalued by 276.81%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.01 - -3.01 | -3.01 | -276.81% |
| P/E | (14.37) - (17.61) | (16.08) | -1045.9% |
| DDM - Stable | (6.77) - (30.30) | (18.53) | -1190.2% |
| DDM - Multi | (10.72) - (37.58) | (16.71) | -1083.2% |
| Market Cap (mil) | 228.75 |
| Beta | 0.39 |
| Outstanding shares (mil) | 134.56 |
| Enterprise Value (mil) | 216.86 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.00% |
| Cost of Debt | 5.00% |
| WACC | 7.86% |